Minerva Neurosciences (NERV) EPS (Weighted Average and Diluted) (2019 - 2026)
Minerva Neurosciences posted quarterly EPS (Weighted Average and Diluted) of -$2.86 for Q1 2026, down 472.0% year-on-year from $0.77 in Q1 2025, and up 91.43% on a QoQ basis from -$33.38 in Q4 2025.
Minerva Neurosciences (NERV) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$2.86 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 472.0% year-over-year to -$2.86; the trailing twelve-month figure through Mar 2026 stood at -$37.03 (down 4615.85% YoY), and the FY2025 full-year result was -$34.67, down 18347.37% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.86, up from -$33.38 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $2.97 in Q3 2024 and bottomed at -$33.38 in Q4 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.13 (2024), against an average of -$2.82.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) surged 388.35%; it then plunged 5860.71% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.26 in 2022, then increased by 4.76% to -$1.2 in 2023, then soared by 53.33% to -$0.56 in 2024, then slumped by 5860.71% to -$33.38 in 2025, then surged by 91.43% to -$2.86 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$2.86 (Q1 2026), -$33.38 (Q4 2025), and -$0.36 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - | -2.86 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.86 |
| Dec 31, 2025 | -33.38 |
| Sep 30, 2025 | -0.36 |
| Jun 30, 2025 | -0.43 |
| Mar 31, 2025 | -0.50 |
| Dec 31, 2024 | -0.56 |
| Sep 30, 2024 | 2.97 |
| Jun 30, 2024 | -1.09 |
| Mar 31, 2024 | -1.13 |
| Dec 31, 2023 | -1.20 |
| Sep 30, 2023 | -1.03 |
| Jun 30, 2023 | -1.12 |
| Mar 31, 2023 | -1.31 |
| Dec 31, 2022 | -1.26 |
| Sep 30, 2022 | -1.29 |
| Jun 30, 2022 | -1.63 |
| Mar 31, 2022 | -1.83 |
| Dec 31, 2021 | -3.99 |
| Sep 30, 2021 | -1.72 |
| Jun 30, 2021 | -0.25 |
| Dec 31, 2020 | -0.18 |
| Sep 30, 2020 | -0.19 |
| Jun 30, 2020 | 0.73 |
| Dec 31, 2019 | -0.77 |
| Sep 30, 2019 | -0.36 |
| Jun 30, 2019 | -0.32 |